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In this issue of the Revista Brasileira de Hematologia e 
Hemoterapia, Holanda et al.1 investigated the hypothesis 
that polymorphisms of the mannose-binding lectin 2 (MBL2) 
gene are associated with infections in patients with chronic 
lymphocytic leukemia (CLL). The authors did not find a 
correlation between genetic changes and frequency of infection 
in a cohort of 116 patients.
Patients with CLL have a highly variable clinical course: 
the majority will have a slowly progressive disease that will 
not require therapy for several years. However, a small but 
important minority will present with rapidly progressive 
disease. Continued efforts have aimed at identifying 
clinical and laboratory parameters that can predict the 
clinical evolution of CLL patients and their eventual need 
for treatment. Most clinicians still rely primarily on clinical 
staging systems (Rai and Binet) to determine the time for initial 
therapy. There are multiple laboratory parameters that have 
some degree of correlation with prognosis, including ZAP-70, 
the CD38 protein expression in CLL cells, and mutational status 
of the immunoglobulin heavy chain (IgVH) gene, but only the 
presence of cytogenetic abnormalities has been well validated 
and can be easily applied in clinical practice for assessment 
and prognosis. 
CLL patients have immune abnormalities that increase the 
rate of infections as well as of autoimmune events. Most will 
experience an infectious event in the course of their disease, 
and approximately half will die from an infectious cause.2 The 
importance of infections cannot be understated, and identification 
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of subjects who are at a particularly increased risk could guide 
preventive choices in the clinical management of CLL patients.
Mannose binding lectin (MBL) is a soluble protein that 
plays an important role in innate immunity. Polymorphisms 
in the promoter region and in exon 1 of the MBL2 gene affect 
MBL plasma concentrations.3 Holanda et al. investigated the 
correlation between polymorphisms of MBL2 and the rates 
of infection in 116 CLL patients. The clinical parameters that 
correlated with infection included CLL clinical stage and 
presence of splenomegaly. Most patients, regardless of whether 
they had infections, had MBL2 gene haplotypes associated with 
high or intermediate expression levels of MBL. There was no 
difference in the distribution of gene polymorphisms among 
patients with versus those without infectious complications.
The study was centered on a pertinent hypothesis, but the 
relatively small sample size prevented a definitive conclusion 
regarding the role of MBL2 gene polymorphisms and the risk 
of infection in CLL. The need for increasingly larger numbers 
of subjects in genetic studies is well-known in a variety of 
scenarios. As genetic testing identifies smaller subgroups 
carrying specific polymorphisms, statistically significance can 
only be achieved by studying very large cohorts of subjects.
Interpretation of infection data in CLL becomes more 
complicated due to the multifactorial nature of the immune 
dysfunction.4 Hypogammaglobulinemia is common5 and 
associated with progressive disease;6 various cell-mediated 
immunity defects have been identified,7,8 and other parts of 
innate immunity, such as the complement system, are also 
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abnormal.9 Only 7% of subjects in this study had haplotypes 
associated with low MBL expression. Therefore, it appears to 
be unlikely that MBL2 gene polymorphisms contribute to the 
risk of infection in most CLL patients. 
The study by Holanda et al.1 highlights the difficulties in 
finding adequate predictive and prognostic factors in CLL. The 
heterogeneity of the patient population and the prolonged 
clinical course of the disease represent significant barriers 
to identify laboratory parameters that can be reliably utilized 
in the clinical practice.10 Large, longitudinal CLL patient 
databases and biorepositories will be fundamental for further 
advancement in the field of laboratory markers for this disease.
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